A mathematical model for the administration of temozolomide: Comparative analysis of conventional and metronomic chemotherapy regimens

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 4, 2013, Pages 1013-1019

  Faivre, C ^a   Barbolosi, D ^a   Pasquier, E ^b,c   Andre N ^a,c,d  

^a University of the Mediterranean Aix Marseille II   (France)

^b CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^c Metronomics Global Health Initiative   (France)

^d TIMONE HOSPITAL   (France)

Author keywords

Angiogenesis; Chemotherapy; Metronomic chemotherapy; Modelization; Pharmacodynamics; Pharmacokinetics; Resistance

Indexed keywords

TEMOZOLOMIDE; ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; DACARBAZINE; DRUG DERIVATIVE;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CHEMOSENSITIVITY; COMPARATIVE STUDY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EFFECT; ENDOTHELIUM CELL; MATHEMATICAL MODEL; MAXIMUM TOLERATED DOSE; PRIORITY JOURNAL; HUMAN; THEORETICAL MODEL;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; ENDOTHELIAL CELLS; HUMANS; MAXIMUM TOLERATED DOSE; MODELS, THEORETICAL;

MLCS; MLOWN;

EID: 84878891226     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2095-z     Document Type: Article

References (29)

1. Addeo R, Caraglia M (2011) Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera? Expert Opin Investig Drugs 20(7):881-895
2. André N, Abed S, Orbach D, Alla CA, Padovani L, Pasquier E, Gentet JC, Verschuur A (2011) Pilot study of pediatric metronomic 4-drug regimen. Oncotarget 2(12):960-965
3. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2(11):1843-1849 (Pubitemid 26384151)
4. Bocci G, Nicolaou KC, Kerbel RS (2002) Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62(23):6938-6943 (Pubitemid 35424084)
5. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60(7):1878-1886 (Pubitemid 30207647)
6. Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP (2000) Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 18(6):1212-1219 (Pubitemid 30159838)
7. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182-1186
8. Gately S, Kerbel R (2001) Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J 7(5):427-436
9. Gompertz B (1825) On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies. Trans Royal Soc of London 115:513-583
10. Hahnfeldt P, Folkman J, Hlatky L (2003) Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol 220(4):545-554 (Pubitemid 36293163)
11. Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105(8):1045-1047 (Pubitemid 30217688)
12. Hirata S, Matsubara T, Saura R, Tateishi H, Hirohata K (1989) Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum 32(9):1065-1073 (Pubitemid 19237859)
13. Kakolyris S, Samonis G, Koukourakis M, Vlachonicolis I, Chalkiadakis G, Kalbakis K, Souglakos I, Agelaki S, Toloudis P, Georgoulias V (1998) Treatment of non-small-cell lung cancer with prolonged oral etoposide. Am J Clin Oncol 21(5):505-508 (Pubitemid 28480506)
14. Kerbel RS (1991) Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays 13(1):31-36 (Pubitemid 21892580)
15. Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4(6):423-436 (Pubitemid 38745528)
16. Klement GL, Kamen BA (2011) Non toxic, fiscally responsible, future of oncology: could it be beginning in the third world? J Pediatr Hematol Oncol 33(1):1-3
17. Kurzen H, Schmitt S, Naher H, Mohler T (2003) Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs 14(7):515-522 (Pubitemid 37083156)
18. Lashford LS, Thiesse P, Jouvet A, Jaspan T, Couanet D, Griffiths PD, Doz F, Ironside J, Robson K, Hobson R, Dugan M, Pearson AD, Vassal G, Frappaz D (2002) Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 20(24):4684-4691 (Pubitemid 36025286)
19. Meille C, Iliadis A, Barbolosi D, Frances N, Freyer G (2008) An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics. J Pharmacokinet Pharmacodyn 35(6):619-633
20. Miller KD, Sweeney CJ, Sledge JGW (2001) Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19(4):1195-1206 (Pubitemid 32176298)
21. Pasquier E, Tuset MP, Street J, Sinnappan S, Mackenzie KL, Braguer D, Andre N, Kavallaris M (2012) Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells. Angiogenesis
22. Pan Q, Yang XJ, Wang HM, Dong XT, Wang W, Li Y, Li JM (2012) Chemoresistance to temozolomide in human glioma cell line u251 is associated with increased activity of o6-methylguanine-dna methyltransferase and can be overcome by metronomic temozolomide regimen. Cell Biochem Biophys 62(1):185-191
23. Panetta JC, Kirstein MN, Gajjar A, Nair G, Fouladi M, Heideman RL, Wilkinson M, Stewart CF (2003) Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. Cancer Chemother Pharmacol 52(6):435-441 (Pubitemid 37491631)
24. Pasquier E, Kavallaris M, André N (2010) Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7(8):455-465
25. Pasquier E, Ciccolini J, Carré M, Giacometti S, Fanciullino R, Pouchy C, Montero MP, Serdjebi C, Kavallaris M, André N (2011) Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget 2(10):797-809
26. Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, Pellegrino A, Dammacco F (1999) Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94(12):4143-4155
27. Wang J, Lou P, Lesniewski R, Henkin J (2003) Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 14(1):13-19 (Pubitemid 36177350)
28. Zhou Q, Guo P, Wang X, Nuthalapati S, Gallo JM (2007) Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens. J Pharmacol Exp Ther 321(1):265-275 (Pubitemid 46456967)
29. Zapletalova D, André N, Deak L, Kyr M, Bajciova V, Mudry P, Dubska L, Demlova R, Pavelka Z, Zitterbart K, Skotakova J, Husek K, Martincekova A, Mazanek P, Kepak T, Doubek M, Kutnikova L, Valik D, Sterba J (2012) Metronomic chemotherapy with the combat regimen in advanced pediatric malignancies: a multicenter experience. Oncology 82(5):249-260